Phase 1 β Early testing in a small group of people (usually 20β80) to evaluate safety, determine safe dosage, and identify side effects.
(16 sites) Australia
Concord Repatriation General Hospital, Concord, New South Wales Macquarie University, Sydney, New South Wales Sunshine Coast University Hospital, Birtinya, Queensland Belgium
KU Leuven, Leuven, Vlaams-Brabant Canada
University of Alberta Hospital, Edmonton, Division of Neurology, Edmonton, Alberta University Hospital - London Health Sciences Centre, London, Ontario Sunnybrook Research Institute, Toronto, Ontario Montreal Neurological Institute and Hospital, Montreal, Quebec Japan
Hokkaido University Hospital, Sapporo, Hokkaido Tokushima University Hospital, Tokushima, Tokushima Toho University Omori Medical Center, Εta-ku, Tokyo Kyoto University Hospital, Kyoto South Korea
Hanyang University Seoul Hospital, Seoul Seoul National University Hospital, Seoul Taiwan
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City Taipei Veterans General Hospital, Taipei